SNPs Study of DPP4 and GLP1R in Chinese and it's Apply in Blood Glucose Regulation With Incretin.

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPN-17011066

Enrollment

Unknown

Registered

2017-04-05

Start date

2016-04-18

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

sitagliptin:sitagliptin po 100mg qd

liraglutide:Liraglutide ih, 0.6mg qd for first week and 1.2mg qd for the last 3 weeks

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. According to diagnostic criteria from Chinese type 2 diabetes prevention and treatment guidelines in diabetes, that published in the Chinese Medical Association Diabetes credits in 2010: Symptoms of diabetes (polydipsia, polyphagia, polyuria, weight loss, itchy skin, blurred vision and other acute metabolic disorders performance caused by hyperglycemia) and RBG=11.1mmol/L, or fasting plasma glucose (FPG)=7.0mmol/L, or plasma glucose of 2 hours post glucose-load=11.1 and patients diagnosed with type 2 diabetes; HbA1c in the range of 7%-10%; 2. Aged 40-70 years; 3. BMI 18-40; 4. Did not accepted any antihyperglycemic therapies during the past 4 weeks, or did not change their antihyperglycemic treatment plan in the past 3 months; 5. Didnt participate in clinical trials within three months; 6. No serious heart, brain, liver and kidney disease; 7. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Have taken any GLP-1 and DPP4-i drugs within recent 1 month; 2. Patients with a weakened immune system; 3. C-peptide < 0.3ng/ml; 4. GLP-1 and DPP4-i drugs allergies; 5. Pregnancy and breast-feeding patients; 6. Patients taking drugs that may affect the metabolism of GLP-1 and DPP4; 7. Patients have serious heart, liver, kidney and respiratory dysfunction; Patients have medullary thyroid carcinoma (MTC) with past history or family history, as well as multiple endocrine neoplasia type 2 syndrome (MEN2); 8. Drug abusing and alcoholism within a year.

Design outcomes

Primary

Measure	Time frame
HbA1c;glycated albumin;SNP Type;Oral Glucose Tolerance Test;	—

Countries

China

Contacts

Public ContactEnwu Long

Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital

dragon984169@126.com+86 028-87393316

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026